Maki Saitoh is a patent agent in the firm's chemical and biotechnology practice group, where she focuses on preparation and prosecution of patent applications for domestic and international clients in a wide range of technical areas including biotechnology, cosmetics, food/beverages, pharmaceuticals, medical devices, polymers, catalysts, batteries, metals/alloys, fibers/textiles, semiconductors, electronic materials, specialty/fine chemicals, glass, packaging/films, dyes/pigments, toners, and coatings. Maki advises clients on effectively prosecuting U.S. applications.
Prior to joining the firm, Maki worked at another IP firm in Alexandria, Virginia, prosecuting patent applications for nearly 10 years. She also worked at Whitehead Institute/Massachusetts Institute of Technology as a researcher investigating the role of stem cells in cancer development. She collaborated with scientists from all over the world.
Maki has experience in conducting prior art searches in English and Japanese, as well as in analyzing patent and technical literature for patentability, invalidity, non-infringement, and freedom-to-operate issues.
“Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled for longevity”
Lamming DW, Ye L, Katajisto P, Goncalves, MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ashima, RS, Guertin DA, Sabatini DM, Baur JA
Science, 2012 Mar 30; 335(6076):1638-43.